PQA Home PQA Home Phone (703) 690-1987
Contact Us Online
"Optimizing Patients' Health by Improving the Quality of Medication Use"
HOME ABOUT PQA ACADEMIC MEASURES MEMBERSHIP MDTs and SAPs RESOURCES
 
PQA Measures


PQA Newsletter



 
Pharmacy Quality Alliance

6213 Old Keene Mill Court
Springfield, VA   22152

Phone: (703) 690-1987
Fax: (703) 842-8150

To contact us, email:
info@pqaalliance.org
or click here.


Measure Concepts Under Discussion
PQA Measures

Each year PQA and its stakeholders identify measure concepts that may be appropriate for development into fully specified performance measures. PQA measures are developed by small, technically proficient Measure Development Teams (MDTs) and Task Forces (TFs) who have applied for or been invited to work on developing specific measure concepts based on their individual skills and experience. MDT and TF members meet via conference line and webinar each month to discuss and develop aspects of the new measure concepts using a consensus-based approach. MDTs and TFs benefit by having their development work reviewed by larger groups, Stakeholder Advisory Panels (SAPs). They may also receive input from the Patient & Caregiver Advisory Panel (PCAP), Implementation Advisory Panel (IAP), and Risk Adjustment Advisory Panel (RAAP).

Once finalized, the MDT or TF will recommend the measure concept to the Quality Metrics Expert Panel (QMEP) for evaluation and refinement.

Below is a list of measure concepts for development in 2017 (continuing or new*):

  • MTM: Medication Therapy Problem Resolution
  • Next Generation MTM Measure*
  • Inappropriate Duplicate Therapy
  •  Immunization Status Assessment within MTM
  • ACIP Compliance Following Immunization Status Assessment
  • ACIP Schedule Completion in Patients with Diabetes*
  • Use of Disease Modifying Therapy in Patients with Relapsing Forms of Multiple Sclerosis
  • Set of three measure concepts:
    • Magnetic Resonance Imaging (MRI) Prior to Initiating or Switching Disease Modifying Therapy (DMT) in Patients with Relapsing Forms of Multiple Sclerosis;
    • MRI to Establish a New Baseline After Initiating or Switching DMT in Patients with Relapsing Forms of Multiple Sclerosis;
    • MRI for Follow-Up in Patients with Relapsing Forms of Multiple Sclerosis Being Treated with DMT



 
© Copyright 2017 Pharmacy Quality Alliance | Site Development & Hosting By ISADEX Corporation | Terms | Privacy Visit Us On Facebook      Visit Us On Twitter      Visit Us On LinkedIn